Can Patient Risk Factors Outperform Antiemetic Guidelines?: Choosing Wisely

JAMA Oncol. 2016 Feb;2(2):232-3. doi: 10.1001/jamaoncol.2015.3757.

Authors

David Warr¹, Carlo DeAngelis², Edward Chow³

Affiliations

¹ Princess Margaret Cancer Centre, Department of Medical Oncology, University of Toronto, Toronto, Ontario, Canada.
² Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada3Department of Pharmacy, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
³ Sunnybrook Odette Cancer Centre, Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.

PMID: 26561746
DOI: 10.1001/jamaoncol.2015.3757

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antiemetics / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Breast Neoplasms / drug therapy*
Decision Support Techniques*
Female
Humans
Nausea / prevention & control*
Practice Patterns, Physicians'*
Vomiting / prevention & control*

Substances

Antiemetics